• Karyopharm Therapeutics posted Q1 net loss of USD 22.39 million, narrowing 5% from year-ago period, as revenue rose 17% to USD 35.07 million.
• Operating loss improved 20% to USD 26.76 million, while product revenue climbed 39% to USD 29.16 million.
• Cash and cash equivalents totaled USD 90.9 million as of March 31, 2026, with existing liquidity expected to fund operating plans to late Q3 2026 and substantial doubt raised about ability to continue as a going concern within one year.
• Phase 3 SENTRY trial met co-primary endpoint for spleen volume reduction, missed co-primary endpoint for total symptom score; company plans FDA engagement on supplemental new drug application filing plan and sees potential compendia inclusion in second half of 2026.
• Completed enrollment in Phase 3 XPORT-EC-042 endometrial cancer maintenance trial with topline data expected mid-2026; agreed with FDA to voluntarily withdraw accelerated approval of XPOVIO diffuse large B-cell lymphoma indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-222827), on May 14, 2026, and is solely responsible for the information contained therein.